AR076949A1 - Derivados de 1h-imidazo-(4,5-c)-quinolinona - Google Patents
Derivados de 1h-imidazo-(4,5-c)-quinolinonaInfo
- Publication number
- AR076949A1 AR076949A1 ARP100101942A ARP100101942A AR076949A1 AR 076949 A1 AR076949 A1 AR 076949A1 AR P100101942 A ARP100101942 A AR P100101942A AR P100101942 A ARP100101942 A AR P100101942A AR 076949 A1 AR076949 A1 AR 076949A1
- Authority
- AR
- Argentina
- Prior art keywords
- imidazo
- treatment
- diseases
- derivatives
- quinolinone derivatives
- Prior art date
Links
- IQYPSFAWXDKDBA-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-c]quinolin-2-one Chemical class C1=CC=CC2=C(NC(=O)N3)C3=CN=C21 IQYPSFAWXDKDBA-UHFFFAOYSA-N 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 108091000080 Phosphotransferase Proteins 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 3
- 150000002632 lipids Chemical class 0.000 abstract 3
- 102000020233 phosphotransferase Human genes 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere al uso de derivados de 1H-imidazo-[4,5-c]-quinolinona y de las sales de los mismos en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido y para la elaboracion de las preparaciones farmacéuticas para el tratamiento de estas enfermedades; a los derivados de 1H-imidazo-[4,5-c]-quinolinona para utilizarse en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido; a un método para el tratamiento contra estas enfermedades, el cual comprende administrar los derivados de 1H-imidazo-[4,5-c]-quinolinona a un animal de sangre caliente, en especial a un ser humano; a las preparaciones farmacéuticas que comprenden un derivado de 1H-imidazo-[4,5-c]-quinolinona, en especial para el tratamiento de una enfermedad dependiente de la cinasa de proteína y/o de lípido; a los derivados 1H-imidazo-[4,5-c]-quinolinona novedosos; y a un proceso para la preparacion de los derivados de 1H-imidazo-[4,5-c]-quinolinona. Reivindicacion 1: Un compuesto de la formula (1) en donde X es O o S; Y es CH o N; R1 es un heteroarilo de 5 miembros sustituido o insustituido; R2 es hidrogeno, alquilo C1-4, o alquenilo C1-4; R3 es un arilo sustituido o insustituido, o heterociclilo; y R4, R5 y R6 son hidrogeno; o una sal farmacéuticamente aceptable, solvato, hidrato o pro-fármaco del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18414109P | 2009-06-04 | 2009-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076949A1 true AR076949A1 (es) | 2011-07-20 |
Family
ID=42697442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101942A AR076949A1 (es) | 2009-06-04 | 2010-06-02 | Derivados de 1h-imidazo-(4,5-c)-quinolinona |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8476294B2 (es) |
| EP (1) | EP2438064A1 (es) |
| JP (1) | JP5596137B2 (es) |
| KR (1) | KR101445458B1 (es) |
| CN (1) | CN102574845B (es) |
| AR (1) | AR076949A1 (es) |
| AU (1) | AU2010255727B2 (es) |
| BR (1) | BRPI1010621A2 (es) |
| CA (1) | CA2763821A1 (es) |
| CL (1) | CL2011003052A1 (es) |
| CO (1) | CO6470887A2 (es) |
| CR (1) | CR20110608A (es) |
| CU (1) | CU24064B1 (es) |
| DO (1) | DOP2011000373A (es) |
| EA (1) | EA020715B1 (es) |
| EC (1) | ECSP11011500A (es) |
| GE (1) | GEP20156267B (es) |
| IL (1) | IL216452A0 (es) |
| MA (1) | MA33332B1 (es) |
| MX (1) | MX2011012943A (es) |
| NI (1) | NI201100209A (es) |
| NZ (1) | NZ596487A (es) |
| PE (1) | PE20120224A1 (es) |
| SG (1) | SG176572A1 (es) |
| TN (1) | TN2011000626A1 (es) |
| TW (1) | TWI464168B (es) |
| UA (1) | UA106074C2 (es) |
| UY (1) | UY32682A (es) |
| WO (1) | WO2010139731A1 (es) |
| ZA (1) | ZA201108439B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| WO2012077031A1 (en) * | 2010-12-06 | 2012-06-14 | Piramal Life Sciences Limited | Substituted imidazoquinoline derivatives |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| EP2781520B1 (en) * | 2011-11-17 | 2016-05-04 | Xuanzhu Pharma Co., Ltd. | Three-ring pi3k and/or mtor inhibitor |
| WO2014141118A1 (en) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
| CN105121411B (zh) | 2013-04-15 | 2017-10-10 | 杜邦公司 | 杀真菌酰胺 |
| US9893299B2 (en) | 2013-09-11 | 2018-02-13 | Merck Patent Gmbh | Heterocyclic compounds |
| WO2015043398A1 (zh) | 2013-09-30 | 2015-04-02 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| US10989719B2 (en) * | 2013-10-11 | 2021-04-27 | National University Corporation Tokyo Medical And Dental University | Methods for treating spinocerebellar ataxia type I using RPA1 |
| JP6290412B2 (ja) * | 2013-11-20 | 2018-03-07 | ベイジン フォーランドファルマ カンパニー リミテッド | イミダゾロン系誘導体、その医薬組成物及び用途 |
| NO2714752T3 (es) | 2014-05-08 | 2018-04-21 | ||
| UA121548C2 (uk) | 2014-06-03 | 2020-06-25 | Ідорсія Фармасьютікалз Лтд | Піразольні сполуки та їх застосування як блокаторів кальцієвих каналів t-типу |
| CN111689963A (zh) | 2015-04-02 | 2020-09-22 | 默克专利股份公司 | 咪唑酮基喹啉和其作为atm激酶抑制剂的用途 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| BR112019007594A2 (pt) | 2016-10-13 | 2019-07-02 | Loyola University Of Chicago | método para bloquear a transmissão do parasita da malária |
| LT3554490T (lt) | 2016-12-16 | 2022-04-25 | Idorsia Pharmaceuticals Ltd | Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių |
| KR102608490B1 (ko) | 2017-02-06 | 2023-11-30 | 이도르시아 파마슈티컬스 리미티드 | 1-아릴-1-트리플루오로메틸시클로프로판의 신규 합성 방법 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| AU2018388404B2 (en) | 2017-12-22 | 2023-11-02 | HiberCell Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN116574099A (zh) * | 2019-09-23 | 2023-08-11 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| US20230380203A1 (en) * | 2021-01-26 | 2023-11-23 | Boe Technology Group Co., Ltd. | Quantum dot light-emitting device, display apparatus and manufacturing method |
| CN116768928A (zh) * | 2023-06-15 | 2023-09-19 | 上海毕臣生化科技有限公司 | 一种3-叔丁基-5-硼酸酯基吡啶的合成方法 |
| CN117384154A (zh) * | 2023-09-04 | 2024-01-12 | 广州医科大学 | 一种吡咯并喹啉酮化合物、合成方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| CA2546117A1 (en) | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| RU2415857C2 (ru) | 2004-09-14 | 2011-04-10 | Новартис Вэксинс Энд Диагностикс Инк. | Имидазохинолиновые соединения |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2628131C (en) | 2005-11-04 | 2012-03-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
| KR20140091718A (ko) | 2006-11-20 | 2014-07-22 | 노파르티스 아게 | 2-메틸-2-［4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조［4,5-ｃ］퀴놀린-1-일)-페닐］-프로피오니트릴의 염 및 결정 형태 |
| KR101472607B1 (ko) | 2007-02-20 | 2014-12-15 | 노파르티스 아게 | 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린 |
| AU2008280105B2 (en) * | 2007-07-24 | 2011-10-20 | Novartis Ag | Use of imidazoquinolines for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| US20090082387A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| WO2009118324A1 (en) | 2008-03-26 | 2009-10-01 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| CA2735932C (en) * | 2008-09-30 | 2013-07-09 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
-
2010
- 2010-06-02 KR KR1020127000098A patent/KR101445458B1/ko not_active Expired - Fee Related
- 2010-06-02 US US12/792,471 patent/US8476294B2/en not_active Expired - Fee Related
- 2010-06-02 AU AU2010255727A patent/AU2010255727B2/en not_active Ceased
- 2010-06-02 CN CN201080034616.0A patent/CN102574845B/zh not_active Expired - Fee Related
- 2010-06-02 CA CA2763821A patent/CA2763821A1/en not_active Abandoned
- 2010-06-02 GE GEAP201012484A patent/GEP20156267B/en unknown
- 2010-06-02 EP EP10721029A patent/EP2438064A1/en not_active Withdrawn
- 2010-06-02 MX MX2011012943A patent/MX2011012943A/es active IP Right Grant
- 2010-06-02 BR BRPI1010621A patent/BRPI1010621A2/pt not_active IP Right Cessation
- 2010-06-02 SG SG2011085487A patent/SG176572A1/en unknown
- 2010-06-02 AR ARP100101942A patent/AR076949A1/es unknown
- 2010-06-02 UA UAA201114398A patent/UA106074C2/uk unknown
- 2010-06-02 JP JP2012513613A patent/JP5596137B2/ja not_active Expired - Fee Related
- 2010-06-02 PE PE2011002047A patent/PE20120224A1/es not_active Application Discontinuation
- 2010-06-02 WO PCT/EP2010/057719 patent/WO2010139731A1/en not_active Ceased
- 2010-06-02 EA EA201101704A patent/EA020715B1/ru not_active IP Right Cessation
- 2010-06-02 MA MA34404A patent/MA33332B1/fr unknown
- 2010-06-02 NZ NZ596487A patent/NZ596487A/xx not_active IP Right Cessation
- 2010-06-03 UY UY0001032682A patent/UY32682A/es not_active Application Discontinuation
- 2010-06-03 TW TW099117977A patent/TWI464168B/zh not_active IP Right Cessation
-
2011
- 2011-11-17 ZA ZA2011/08439A patent/ZA201108439B/en unknown
- 2011-11-17 IL IL216452A patent/IL216452A0/en not_active IP Right Cessation
- 2011-11-21 CR CR20110608A patent/CR20110608A/es unknown
- 2011-11-30 CU CU2011000221A patent/CU24064B1/es not_active IP Right Cessation
- 2011-11-30 NI NI201100209A patent/NI201100209A/es unknown
- 2011-12-02 EC EC2011011500A patent/ECSP11011500A/es unknown
- 2011-12-02 DO DO2011000373A patent/DOP2011000373A/es unknown
- 2011-12-02 CL CL2011003052A patent/CL2011003052A1/es unknown
- 2011-12-05 TN TNP2011000626A patent/TN2011000626A1/en unknown
- 2011-12-12 CO CO11170918A patent/CO6470887A2/es active IP Right Grant
-
2013
- 2013-05-24 US US13/901,849 patent/US20140005163A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076949A1 (es) | Derivados de 1h-imidazo-(4,5-c)-quinolinona | |
| MA55890B1 (fr) | Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl | |
| PE20221038A1 (es) | Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores | |
| BRPI0714908B8 (pt) | derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| WO2017180769A1 (en) | Small molecules for immunogenic treatment of cancer | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
| EP2285373A2 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
| RU2009144538A (ru) | Новые циклические пептидные соединения | |
| AR050180A1 (es) | Derivados de guanidina y sus usos terapeuticos | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| RU2008125040A (ru) | ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
| ECSP10010247A (es) | Derivados heterocíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |